Spinal Implants Market Top 7 Key Players Revenue, Share, Demand and Forecasts Till 2027

 Spinal Implants Market Overview:

Spinal implants are useful for the treatment of spinal deformities. Market Research Future (MRFR) has published a research report about the global spinal implants market that infers boost with 5.5% CAGR during the forecast period between 2022 and 2027.

Factors that are enhancing the market growth for spinal implants include the development of safer technology, innovation of cost-effective spinal devices, and increasing demand for minimally invasive spine surgery. However, some factors that can hamper the growth of the market include lack of reimbursements in developing countries, high procedural costs, and stringent regulatory guidelines for the approval of new medical devices.

Key Players:

The key players in the global Spinal Implants Companies include Accel Spine (USA), AESCULAP (USA), Alliance Spine (USA), Alphatec Holdings, Inc. (the USA), Amedica Corporation (USA), Apollo Spine (USA), Ascendx Spine (USA), A-Spine (Taiwan), Back 2 Basics Spine (Canada), Captiva Spine Inc. (USA), Centinel Spine (USA), Depuy Synthes Inc. (Johnson & Johnson) (USA), Exactech Inc. (USA), Globus Medical, Inc. (USA), Integra LifeSciences (USA), K2M Group Holdings, Inc. (the USA), LDR Holding Corporation (USA), Life Spine (USA), Medtronic, plc (Ireland), NLT Spine (USA), NuVasive, Inc. (the USA), Orthofix International N.V. (Netherlands), Paradigm Spine LLC (USA), Precision Spine (USA), Premia Spine (Israel), Quandary Medical LLC (USA), Reliance Medical Systems (USA), RTI Surgical, Inc. (USA), SI-BONE (USA), Spine Frontier (USA), Spineart Geneva SA (Switzerland), SpineGuard (France), Spinal Solutions Inc. (USA), Stryker Corporation (USA), and Zimmer Biomet Holdings, Inc. (USA).

Segmentation:

The global Spinal Implants Market has been segmented on the basis of material, procedure, product, and lastly region. Material based segmentation of this market segments the market into plastic, stainless steel, titanium, titanium alloy, and others. Based on the procedure, the market has been segmented into minimally invasive surgery (MIS), open surgery, and others.

The product-based segmentation covers spine biologics, spinal bone stimulators, spinal fusion devices, non-fusion devices/motion preservation devices, Vertebral Compression Fracture (VCF) treatment devices, and others. Spine Biologics have been sub-segmented into bone graft substitutes, cell-based matrix, and spinal allografts. The bone graft substitutes have been further segmented into bone morphogenetic proteins and synthetic bone grafts. The further segmentation of spinal allografts covers demineralized bone matrix and machined bones allograft.

The spinal bone stimulators have been sub-segmented into invasive spine bone stimulators and non-invasive spine bone stimulators. The non-invasive spine bone stimulators have been further segmented into capacitive coupling (CC) & combined magnetic field (CMF) device, and a pulsed electromagnetic field device.

The spine fusion devices segment has been sub-segmented into cervical fixation devices, interbody fusion devices, thoracolumbar devices, and others. Cervical fixation devices have been further segmented into anterior cervical plates, clamps, hook fixation systems, plates & screws, and wires. Interbody fusion devices have been further segmented into bone interbody fusion devices and non-bone interbody fusion devices. Thoracolumbar devices have been further segmented into anterior lumbar plates, crosslinks, hooks, lumbar plates, pedicle screw, and wires & cables.

Non-fusion devices/motion preservation devices have been sub-segmented into annulus repair devices, artificial discs, dynamic stabilization devices, and nuclear disc prostheses. Artificial discs have been further segmented into artificial cervical discs and artificial lumbar discs. Dynamic stabilization devices have been further segmented into facet replacement products, interspinous process spacers, and pedicle screw-based systems. VCF treatment devices have been further segmented into balloon kyphoplasty devices and vertebroplasty devices.

Regional Analysis:

The regional segmentation of the global spinal implants market has segmented the market on the basis of continents named The Americas (North America & South America), Europe, Asia Pacific, and the Middle East and Africa (MEA). The Americas dominate the global spinal implants market due to the advancement in manufacturing processes, the contribution of nanotechnology to the pharmaceutical packaging market, and technological innovation. Due to the availability of advanced technology and the best medical facilities, North America is a bigger market than South America. In this region, the most important country-specific markets are the United States of America (USA) and Canada. Many key players in the market are based in the USA. In South America, the strongest economies that can emerge as lucrative markets someday are Argentina and Brazil.

Europe is an important market because, after North America, it is the most technologically advanced market. Due to the reasons same as the Americas, Western Europe is a bigger market than Eastern Europe. In Western Europe, the most significant country based markets are France, Germany, Italy, Spain, and the United Kingdom (UK), followed by the rest of Western Europe. In Europe, the spinal implants market is growing due to due to its increasing geriatric population and the growing demand by geriatric people for the spinal implants and devices.

According to the report, Asia Pacific is an emerging market due to the rapid urbanization and the gradual increase in obesity which has led to increased spinal disorders. The most important factors that are creating the demand for spinal implants and driving the market include advanced treatments, increasing awareness with regards to spinal problems and novel spine treatment techniques, increasing healthcare expenditure, and increasing government support for advanced healthcare technologies. The primary country-specific markets in this region are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific region.

In the MEA region, the market is small and limited. Reasons for the limited market growth in this region are lack of awareness, lack of education, lack of technological development, political instability and healthcare not being considered a priority by the government. In this region, the maximum revenue is generated by the country-specific markets namely Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates (UAE), followed by the rest of the MEA region.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Throat Lozenges Market Advanced Technologies, Industry Size, Iconic Revenue, Shares, Trends and Demand by 2027

 Segmentation:

The global throat lozenges market is segmented based on ingredients types, applications, and usage. By ingredients types, the market is segmented into menthol throat lozenges and non-menthol throat lozenges. Menthol throat lozenges are sub-segmented into mint, eucalyptus, peppermint oil and others. Non-menthol throat lozenges are sub-segmented into pectin, zinc gluconate glycine, and others. By usage, the market is segmented into antibacterial lozenges, pharmaceutical lozenges, and others. By application, the market is segmented into throat diseases, cough and cold, throat soreness and others.    

Competitive Landscape

The global Throat Lozenges Market is consolidating, and it is expected that many new vendors will enter the market in future, bringing fiercer competition for the existing market players. Established players are implementing various strategies such as collaboration, mergers, partnerships and new product launches to strengthen their footprint in the market. GlaxoSmithKline Pharmaceuticals Limited (UK), Procter & Gamble (P&G) (US), Bliss GVS Pharma Ltd (India), Hershey Foods Corp. (US), Thornton & Ross, Pfizer, Inc (US), United Confections Throat lozenge (UK), Perfetti (Italy), Roshen Confectionery Corp (Ukraine), united confections(US), Yildiz Holding (Turkey), August Storck KG (Germany), Ezaki Glico Co., Ltd. (Japan), CRM Group (Brazil) and Crown Confectionery Co. Ltd. (South Koera) are the key players dominating the market.

Market Overview:

What is Throat Lozenges? Lozenges are solid medicated confections that dissolve in the mouth, intended to treat infection of mouth or pharynx. Lozenges are made up of analgesics like Ketamine, paracetamol, codeine; antifungal like ketoconazole, amphoterisin B, miconazole; anesthetics like benzocaine; antimicrobials like artesunate and their composition vary from company to company. They are used to get temporary relief from coughs, throat soreness and might also be prescribed to patients suffering from pharyngitis. They are available over the counter or may be prescribed by a physician. The affordability and reliability of throat lozenges are of the driving factors for market growth.

Every year 10-15% of the world’s population suffers from common cold, says WHO. Increase in global geriatric population and increasing prevalence of allergy and common cold are common drivers of the market. The global air pollution levels are reaching epidemic proportions which are one of the causes of respiratory infections, mainly throat infections. Additionally, a gradual increase in smoking across the globe is another cause of throat irritation. The market is also driven by unemployed and less developed economies where self-diagnosis and medication practices are quite common. According to a research report published by Market Research Future (MRFR), the global throat lozenges market is set to capture a CAGR of 3.5 % during the forecast period 2022-2027.

The lozenges market is a subset of the throat remedies market so growth in throat remedies market will result in a growth of the throat lozenges market.

Increase in labor costs, intensive advertising expenditures are some of the hindrances to the market growth. Also, short-term effect and availability of herbal alternatives, which have no side-effects hamper the growth of the market. The throat lozenges market sales are subject to fluctuations as cold and flu-related problems are less likely to happen during the summer season. Patients who have asthma cannot take throat lozenges, allergies, are on heart disease medication or pregnant. Moreover, throat lozenges contain considerable amounts of sugar and hence are not preferred by diabetic and health-conscious people. Innovations are being made in throat lozenges to enhance taste, reduce calorie content, and modify the drug release characteristics.

Regional Analysis:

The key markets for the global throat lozenges are the Americas, Europe, and Asia-Pacific. America accounts for the most significant share of the market owing to the presence of many of key manufacturers in the region. Besides, incidents of cough and cold are widespread in the region due to frigid temperatures. Europe ranks the second followed by Asia-Pacific.   

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Forecast Indicators Trending Lucrative Growth Till 2027

 Market Highlights

It is estimated that the global IPF treatment market is expected to register a CAGR of 12.3% during the forecast period of 2022 to 2027, with a market value of USD 2,237 million in 2022.

IPF is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. However, the high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment market.

The global idiopathic pulmonary fibrosis market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in September 2022, FibroGen, Inc. announced that the grant of Fast Track designation by US Food and Drug Administration (FDA) for the company’s anti-CTGF antibody, Pamrevlumab, for the treatment of patients with IPF.

Key Players

Some of the key players in the global IPF treatment market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibrogen, Inc., Cipla, Merck & Co., Inc., Prometic Life Sciences Inc., and others.

Segmentation

The global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has been segmented based on treatment.

The market, based on treatment, has been further divided into drug class, oxygen therapy, lung transplant, and others. The drug class segment is likely to hold a major share in the market due to the increasing adoption of the drugs for the treatment of IPF and wider preferability. The oxygen therapy segment is predicted to be the fastest growing due to the increasing inclination of medical professionals towards this therapy for the treatment of IPF.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The IPF treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European IPF treatment market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The IPF treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Bronchoscopes Market Value Chain, Future Analysis, Industry Growth by 2027

 Key Players:

The global market consist of players such as Ambu Inc, Boston Scientific Corporation, Cogentix Medical, Fujifilm Holdings Corporation, KARL STORZ GmbH & Co. KG, Olympus Corporation, PENTAX Medical, and Richard Wolf GmbH are some of the prominent players at the forefront of competition in the global bronchoscopes market and are profiled in MRFR Analysis report.

Bronchoscopes Market - Overview

According to a recent study report published by the Market Research Future analysts, the global bronchoscopes market is growing at a moderate pace; mainly due to increasing prevalence of respiratory tract diseases such as lung cancer, and COPD among others; increasing preference for minimally invasive procedures and increasing number of disposable bronchoscopes procedures. Increasing geriatric population, and changing environmental conditions leading to high air pollution have also fuelled the growth of the market

That being said, there are few obstacles as well in this market. Increased incidence of infection by bronchoscopes, and high costs of the bronchoscopes which may affect the growth of this market.

Bronchoscopes Market   - Competitive Analysis

The global Bronchoscopes Market is well established market with number of products available in the market. There are few companies involved in the development of the bronchoscopes which are now widely used all across the world.  A limited number of companies are working in the bronchoscopes market. Through extensive research, it is found out that the market players have adopted the strategy of improving the bronchoscopes, acquisition and collaboration. On the basis of the market study, we found some key players operating in this market: Ambu Inc., Boston Scientific Corporation, Cogentix Medical, Fujifilm Holdings Corporation, Olympus Corporation, Pentax Medicals, and KARL STORZ GmbH & Co. KG. Olympus Corporation is one of the leading players in the market with a huge global presence and over 39,727 employees.

Some of the key developments from the market players are as follows.

In August 2017, PENTAX medical announced the launch of a new ultrasound video bronchoscope (EBUS) in combination with Hitachi’s innovative ultrasound systems. In June 2017, The Company announced the collaboration with AOHUA to improve the standard of patient care and quality of healthcare. Earlier in January 2017, The company acquired C2 Therapeutics to expand interventional endoscopy offering.

In July 2016, PENTAX Medical launched new high-definition pulmonology endoscopy system to deliver outstanding HD image quality.

In June 2017 Another big company in the market, Boston Scientific Corporation launched Alair bronchial thermoplasty therapy in India.Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. Back in November 2016, Company completed acquisition of EndoChoice Holdings, Inc. which is a Georgia based company focused on the development and commercialization of infection control products, pathology services and single-use devices.

There are some developments from other players as well. In May 2016, Ambu Inc. launched Ambu aScope 3 Large bronchoscope. Earlier in January 2016, this Ambu aScope 3 was approved for sale in China.

Global Bronchoscopes Market - Regional Analysis

The Americas accounts for the major share of the market owing to the huge patient population, well-developed technology, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the number of adults with diagnosed chronic bronchitis and emphysema were 9.3 million and 3.5 million respectively. Additionally, according to the American Thoracic Society, in 2012, chronic obstructive pulmonary disease (COPD) affects 6.8 percent of adults and was responsible for about 700,000 hospitalizations and 127,000 deaths annually in the US. People in this region are health conscious and are willing to spend more on healthcare. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% and reached USD 3.2 trillion, and the healthcare spending in the U.S. in 2014 was USD 9,532 per person.

Europe accounts for the second largest market, which is followed by Asia Pacific. Increasing government support for research & development, well-developed healthcare infrastructure, and presence of geriatric population have driven the bronchoscopes market. Asia Pacific is the fastest growing bronchoscopes market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

UTI Treatment Market Share Analysis, Strategies, Revenue and Forecasts to 2027

 UTI treatment Market Overview:

The market for Urinary Tract Infections (UTI) is a well- established space, flooding with the numerous treatment options ranging from Home remedies, Alternative medicines to Antibiotics. Due to the growing prevalence of UTI, the market for UTI Treatment is escalating exponentially.

Acknowledging the exponential growth, the market is observing currently; Market Research Future (MRFR) in its recently published study report asserts that the UTI Treatment market is forecasted to reach USD 9.89 Bn. by 2027 with a CAGR of 3.6 % from 2022 to 2027.

In addition to the growing incidences of urinary tract infections, factors impacting the UTI treatment Market growth include the rise in hospital-borne infections or nosocomial infections, childbirth, old age, obesity, and the growing health awareness, especially towards women health. However, the rising cases of UTI associated with the usages of the catheter are considered as the largest risk factor supporting the market growth.

On the flip side, factors such as incidents of drug resistance, and large unmet clinical needs are expected to obstruct the market growth. Nevertheless, increasing incidence of chronic diseases resulting in catheter use and low immunity etc. are expected to support the market growth.

Leveraging to the modern age, people have adopted unhealthy lifestyles which mirrors the prevalence of damaged immune system and various disorders. Immense of stress, lack of quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the immunodeficiency disorders.  All these factors commutatively fuel the occurrences of UTI.

Key Players:

Some of the leaders driving the global UIT market include Novartis AG, Bayer AG, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Cipla Inc., Johnson & Johnson, GlaxoSmithKline, and Dr. Reddy’s Laboratories Ltd.

Global UTI Treatment Market   - Segmentations

The MRFR analysis is segmented into four key dynamics for the convenience of understanding;

By Drug Class              : Comprises - Quinolones, Aminoglycosides, β-lactam, and Azoles among others.

By Clinical Indications           : Urethritis, Cystitis, and Pyelonephritis among others.

By End-Users              : Hospitals and Self-administered among others.

By Regions                              :  North America, Europe, APAC and the Rest-of-the-World.

The subsegment Quinolones accounts for almost 45% of market share whereas the subsegment Aminoglycosides segment holds the second-largest market share by drug class in the global UTI treatment market.

Global UTI Treatment Market - Regional Landscape

North America region accounts for the leading market for UTI Treatment, acquiring the largest market share, globally. Various factors substantiating the market growth include the availability of specialized treatment centers, the presence numerous players, solid support from the government and private entities, improved patients experience with high quality and low-cost services in the region.

However, the regulatory changes in the US such as the implementation of Affordable Care Act and Hospital Readmissions Reduction Program alongside the Medicare initiative to penalize unnecessary patient readmissions is expected to take a toll on the UTI Symptoms market in the US.

Europe & Asia Pacific region accounts for the second & third largest market respectively in the global UTI Treatment market.

Whereas, the increasing patient pool coupled with the demand for more treatment centers drive the market growth in the APAC region. Owing to the rising funding and proliferating infrastructures for healthcare, mainly in countries like China and India the Asia Pacific market is emerging as one of the lucrative markets, globally.

Global UTI Treatment Market - Competitive Landscape

The global UTI Treatment market is fragmented with a large number of players.  Drug class - Quinolones is curtailing the product development strategy with its efficiency and efficacy.  However, the increasing cases of drug resistance have opened doors for new drug development, providing scope for a new market leader. The rise of spurious and counterfeit medicines has reduced the total market revenues and at the same time displaced standard drugs off the market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Middle East and Africa Critical Care Equipment Market Forecast Indicators Trending Lucrative Growth Till 2027

 Market Highlights

The Middle East and Africa critical care equipment (CCE) market has been evaluated to be growing moderately and is expected that it will continue to grow at the same pace in future as well. This market was US$ 681.2 million in 2016 and is expected to reach US$ 1061.4 million by 2023 growing at the CAGR of 5.7%. Critical care is very important medical procedure planned to cure critical medical conditions such as severe illness, injuries or both. Hospitals have their own critical care unit (CCU) or commonly known as intensive care unit (ICU) to monitor, diagnose and treat patients under controlled medical conditions with the help of critical care equipment. These are technologically advanced devices which monitors and collects accurate data about patients’ current medical condition. CCE also provides life support to patients so that patients can maintain organ functioning in life threatening medical conditions including severe injuries, illness or both.

Middle East and Africa is one of the prominent and growing market for the healthcare sector. Due to increase in per capita income, the expenditure on healthcare is also increasing in this region. Non-communicable diseases like stroke and heart diseases are rising rapidly and are major market driver for critical care equipment in these regions. The critical care equipment market in these regions is expected to grow at the CAGR of 10% annually and which boosts growth of the overall healthcare industry. Hospitals in these regions are spending about 20%-30% of their budget on critical care units. Medical equipment manufacturers are spending money on R&D to develop more advance and innovative products for the CCE market. Continuous innovation and growing adoption of new technology are leading the growth of this market.

Test the market data and market information presented through more than 40 market data tables and figures spread over 65 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Middle-East and Africa critical care equipment (CCE) Market Research Report –Forecast till 2022.”

Middle-East and Africa Critical Care Equipment (CCE) Market Players:

There are plenty of large and small market players which operates in this Middle East and Africa Critical Care Equipment Market all over Middle East and Africa region, namely Johnson & Johnson Services, Inc. (US), General Electric Company (US), Medtronic (Republic of Ireland), Siemens Healthcare Private Limited (Germany), Baxter (US) and Koninklijke Philips N.V. (Netherlands)

Considering the scenario of Middle East and Africa market, UAE region is believed to be the largest market for critical care equipment in these regions. Moreover, Saudi Arabia market is also growing and is the second largest market for CCE.  On the other hand, Egypt’s market is expected to grow at a steady pace in Middle-East critical care equipment market during the forecasted period. Rest of the Middle East and Africa region is likely to have a limited but steady growth in this market.

Segmentation:

Middle East and Africa Critical Care Equipment Market has been segmented on the basis of type of Critical Care Equipment which includes patient monitor, medical ventilator, dialysis, IV pumps, infusion pump, suction apparatus and others. On the basis of end user of the market, the same has been is segmented into hospitals, research laboratories and others.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Anti-Viral Drugs Market | Projected to Grow Radiantly by Top Players Revenue and Growth Rate by 2027

 Anti-Viral Drugs Market - Highlights

Anti-viral drugs are used to treat viral infections and are the only agents acting against viruses as either other drugs are ineffective or too toxic. The market segment of anti-viral drugs is driven by factors such as rise in healthcare expenditure, growing research and development investment, emergence of virus life-threatening diseases like bird flu, strong development pipeline and increasing incidence rates of viral infections particularly HIV. WHO has estimated that in 2015 about 36.7 million people are suffering from HIV/AIDS with 1.1 million deaths occurring due to AIDS-related illness the emergence of donor funding in the treatment of the disease has also increased the demands of anti-viral drug market. Strong research pipeline coupled with rise in research and development investment antiviral medicine will be the market driver of the future.

The constraints on the market include side effects associated with treatment, the cost of the therapy and poor efficacy and effectiveness of the drugs.

Global Anti-Viral Drugs Market - Key Players

The major participants of this market are: Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, AstraZeneca AB, Cipla Inc. and others.

Global Anti-Viral Drugs Market - Segmentation

Global Anti-Viral Drugs Market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.

Global Anti-Viral Drugs Market

The global anti-viral drugs market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. The global anti-viral drugs market is expected to grow with CAGR of ~6.9% during the forecast period. There has been consolidation of the market as a few players have come to dominate the market due to acquisitions and mergers.

Global Anti-Viral Drugs Market - Regional Analysis

Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013